MedTrace Logo

Stem Cell Therapy as Adjunct to Revascularization

NCT00463853 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2014-06-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether it is safe to receive an injection of your own bone marrow adult stem cells (autologous BM-MNC) to your heart wall during coronary artery bypass graft (CABG).

Conditions

  • Coronary Arteriosclerosis
  • Coronary Artery Bypass Graft
  • Myocardial Revascularization

Interventions

PROCEDURE

Autologous stem cell therapy

PROCEDURE

CABG

RADIATION

CMRI

Sponsors & Collaborators

Principal Investigators

  • G. Russell Reiss, MD · VA Salt Lake City Health Care System, Salt Lake City

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-07-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00463853 on ClinicalTrials.gov